BioWorld

Jan. 10, 2006

CancerVax, Micromet Enter $127M Merger Agreement

In a transaction that augments one company's pipeline and gives the other U.S. market access, CancerVax Corp. and Micromet AG signed a definitive merger agreement. (BioWorld Today) Read More

Replidyne Submits NDA For Oral Antibiotic Drug Orapem

More Good Phase III Results With Celgene's Thalidomide

Xytis Series B: $25M For Trials In Schizophrenia, Brain Injury

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026